Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 3, 2014, Pages 255-260

  Srimuninnimit, Vichien ^a   Sriuranpong, Virote ^b   Suwanvecho, Suthida ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c BUMRUNGRAD INTERNATIONAL HOSPITAL   (Thailand)

Author keywords

Gemcitabine; Hepatoma; Sorafenib

Indexed keywords

GEMCITABINE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DEOXYCYTIDINE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84906094507     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12191     Document Type: Article

References (17)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta 2010.
2. Remontet L, Esteve J, Bouvier AM etal. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003; 51: 3-30.
3. Jemal A, Murray T, Ward E etal. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
4. National Cancer Institute. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer [Internet]. 2009. [Cited 30 Nov 2011.] Available from URL: http://seer.cancer.gov/statfacts/html/livibd.html.
5. Llovet JM, Di Bisceglie AM, Bruix J etal. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
6. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-443.
7. Giglia JL, Antonia SJ, Berk LB etal. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010; 17: 120-129.
8. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008; 359: 378-390.
9. Abou-Alfa GK, Johnson P, Knox JJ etal. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160.
10. Matsumoto K, Nagahara T, Okano J etal. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 2008; 20: 863-872.
11. Louafi S, Boige V, Ducreux M etal. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390.
12. Taïeb J, Bonyhay L, Golli L etal. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98: 2664-2670.
13. Richly H, Kupsch P, Passage K etal. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004; 42: 650-651.
14. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
15. Yau T, Chan P, Ng KK etal. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-436.
16. Leung TW, Patt YZ, Lau WY etal. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681.
17. Lee J, Park JO, Kim WS etal. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 385-390.